BIOMARKER DISCOVERY SERVICES

Find biomarkers to catalyze breakthroughs

Sapient provides bespoke metabolomics and lipidomics services to biopharma researchers who are driven to enhance the precision and efficacy of drug therapies.

What do you want to discover?

Sapient is here to help you derive rapid, high-quality insight from the rapid measure of complex human chemistry.

Nontargeted Discovery Metabolomics & Lipidomics

Our nontargeted discovery services allow for broad profiling of the tens of thousands small molecules in circulation, enabling rapid identification of known biomarkers and importantly, amplifying your ability to discover biologically relevant biomarkers that may not yet be known.

Target Metabolite
and Lipid Panels

Sapient can also support studies that seek to analyze specific metabolites or lipids with our focused chemical panels. Benefit from the same rapid turnaround of data, analyses, and insights for the subset of biomarkers that interest you most.

DISCOVERY AS A SERVICE

Discovery that fits your context of use

We customize our discovery metabolomics and lipidomics services to your needs by understanding the details of the biological questions you want to answer and designing a project that provides you with the data you need, including for:

Target Identification

Identify therapeutic targets that may be involved in the pathogenesis of a specific disease.

Target Validation

Confirm a target’s role in disease process and/or the effects of pharmacological modulation of the target.

Target Engagement

Demonstrate the drug reaches its intended target with measurable binding effect.

Pharmacodynamics

Evaluate the biological activity of a drug.

Early Disease Detection

Identify genetic and/or environmental factors that predispose to disease and/or cause disease progression.

Disease Progression

Monitor disease status, the occurrence of new disease effects, and/or change in disease severity.

Patient Stratification

Select patients according to disease-based or drug-based biomarker signatures.

Clinical Trial Enrichment

Select patients most likely to respond to a treatment to increase study power while reducing study size.

Safety Profiling

Assess the presence or extent of toxicity related to an intervention or drug exposure.

Companion Diagnostics

Identify predictive biomarkers that identify suitable patients for a treatment.

Ultimately, we seek to identify biomarkers that can be used to align the right patient, with the right disease, with the right therapy.

Case Study: Discovery of an Early Diagnostic Biomarker for NASH

Learn how Sapient discovered a single biomarker in blood that predicts disease development more than 10 years in advance.

Case Study: Discovery of PD-1 Pathway Biomarkers of Target Engagement

See how Sapient used its Human Biology Database to discover circulating biomarkers that robustly associate with genetic variants present in the PD-1 pathway.

Working together

Faster data delivery for rapid time-to-insight.

From rapid turnaround times to flexible engagement options, including pilot programs to kick-start discovery, we’re here to accelerate your R&D.

Let's Talk